EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone

Xinzhi Hu iD, Yiyang Liu iD, Weizhuang Yuan iD, Zongmuyu Zhang iD, Shun Li iD, Anqi Cheng iD, Qiuyu Yu iD, Haoyao Guo iD, Yinxi Zou, Mingli Li iD, Caiyan Liu, Yan Xu iD und 1 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.124.041251 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Xinzhi Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical S…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Plaque, Atherosclerotic, Antibodies, Monoclonal, Humanized, Intracranial Arteriosclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type‐9 inhibitor for intensive lipid‐lowering, on intracranial atherosclerotic stenosis.

Methods

From a prospectively established high‐resolution magnetic resonance imaging database, consecutive patients with intracranial atherosclerotic stenosis (≥50%) with 2 detections of high‐resolution magnetic resonance imaging over 6 months were included in this retrospective analysis. Eligible patients were grouped by treatment: evolocumab add‐on (evolocumab + ) versus no evolocumab (evolocumab − ). The primary outcome was plaque response (plaque regression >5%). Secondary outcomes included the percentage of changes in plaque burden and stenosis degree. Logistic and linear regression analyses were used to estimate the association between evolocumab use and the above outcomes in both the general and subgroup (intensive versus nonintensive statin) analyses.

Results

Among 179 statin‐treated patients (50 evolocumab + , 129 evolocumab − ), evolocumab add‐on therapy was associated with higher plaque response (68.0% versus 34.1%), greater plaque burden reduction (median [interquartile range]: −8.2% [−11.4%, −1.8%] versus –1.9% [−6.7%, 4.4%]), and stenosis degree reduction (−15.3% [−33.7%, −1.3%] versus –5.4% [−25.8%, 12.3%]). Adjusted regression analyses showed significant associations between evolocumab use and plaque response (odds ratio [95% CI], 6.67 [2.80, 16.91]), plaque burden reduction (estimate [95% CI], −7.0% [−11.5%, −2.5%]), and stenosis degree reduction (estimate [95% CI], −20.3% [−31.7%, −7.0%]). Subgroup analyses according to background statin intensity showed consistent associations.

Conclusions

Evolocumab add‐on therapy over 6 months was associated with intracranial atherosclerotic plaque regression compared with statin therapy alone. However, given the retrospective design and potential between‐group differences, these findings require further confirmation in prospective randomized controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsPlaque, AtheroscleroticAntibodies, Monoclonal, HumanizedIntracranial ArteriosclerosisAnticholesteremic AgentsPCSK9 InhibitorsHumansMaleFemaleRetrospective StudiesAgedDrug Therapy, CombinationMiddle AgedTreatment OutcomeMagnetic Resonance ImagingProprotein Convertase 9

Stichwörter der Autor:innen

PCSK9 inhibitorhigh‐resolution MRIintracranial atherosclerotic stenosisplaque regressionstatin

Substanzen

evolocumabHydroxymethylglutaryl-CoA Reductase InhibitorsAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Neurology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.
  • Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China.

ORCID-Profile: Xinzhi Hu, Yiyang Liu, Weizhuang Yuan, Zongmuyu Zhang, Shun Li, Anqi Cheng, Qiuyu Yu, Haoyao Guo, Mingli Li, Yan Xu, Weihai Xu

Zitieren

APA

Hu, X., Liu, Y., Yuan, W., Zhang, Z., Li, S., Cheng, A., Yu, Q., Guo, H., Zou, Y., Li, M., Liu, C., Xu, Y., & Xu, W. (2025). Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.041251

Vancouver

Hu X, Liu Y, Yuan W, Zhang Z, Li S, Cheng A, et al. Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.041251

BibTeX
@article{Hu2025,
  author = {Hu, Xinzhi and Liu, Yiyang and Yuan, Weizhuang and Zhang, Zongmuyu and Li, Shun and Cheng, Anqi and Yu, Qiuyu and Guo, Haoyao and Zou, Yinxi and Li, Mingli and Liu, Caiyan and Xu, Yan and Xu, Weihai},
  title = {Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.124.041251}
}
Kostenlos starten →